linkedin

Press Releases

Samsung BIO Insight

Samsung Biologics’ Super Plant 4, How the world’s largest biomanufacturing plant will drive clients’ success

Samsung_Biologics?_Super_Plant%204_How_the_world?s_largest_biomanufacturing_plant_will_drive_clients?_success_thumbnail.jpg
 

This month, Samsung Biologics commenced GMP operations at its newest Plant 4. With the world’s largest contract manufacturing capacity, the company plans to maximize operational efficiency for its clients and further strengthen its foothold in the industry as an end-to-end service partner.

 

 

Breaking world records

 

In just 23 months since its groundbreaking in November 2020, Samsung Biologics delivered on its commitment to begin partial operations at Plant 4.

 

As the world’s largest single biomanufacturing plant, Plant 4 is expected to have a production capacity of 240,000 liters upon full completion next year, giving Samsung Biologics a total of 604,000 liters’ capacity, amounting to over a quarter of the total global CDMO production, at Bio Campus I.

 

SamsungBiologics_Plant4_Article_1.jpg

Plant 4 groundbreaking ceremony (Nov. 2020)

 

SamsungBiologics_Plant4_Article_2.jpg

Samsung Biologics’ total manufacturing capacity

 

Samsung Biologics offers end-to-end services, from early stage development to commercial manufacturing, including quality management. The company also has a diverse lineup of bioreactors, from 1,000 liters to 15,000 liters, enabling flexibility for small batch clinical trial materials production or large-scale commercial manufacturing.

 

Samsung Biologics can swiftly and efficiently manufacture high-quality biopharmaceuticals based on N-1 perfusion technology, data digitalization and cyber security integrity. Plant 4 incorporates the know-how, technologies and best practices learned at Plants 1, 2 and 3.

 

 


Investing in a sustainable tomorrow

 

As a sustainable CDMO, Samsung Biologics invested in eco-friendly technology throughout Plant 4 to mitigate its emissions. A 1,300 kW solar power generator was installed on the plant’s roof over an area of 4,000 to partially generate energy for the plant.

 

In order to reduce direct GHG emissions, the company adopted the ‘Factory Energy Management System,’ to monitor and analyze energy consumption to help reduce emissions and waste. Through its environmental management strategy, the company plans to take additional measures going forward to enhance its recycling process when it comes to disposables and water use, reduce energy consumption by switching to high-efficiency boilers, and prevent air pollution to help tackle climate change.

 

SamsungBiologics_Plant4_Article_2-1.jpg
Solar panels installed on Plant 4

 

 

 

Accelerating excellence

 

Plant 4 can handle a product’s entire production life cycle within a single site. It will also be equipped with multiple digital solutions to achieve data integrity and transparency, while eliminating the potential of human error.

 

Samsung Biologics plans to further boost client satisfaction through continuous innovation and investments, as well as the construction of Bio Campus II, which will host Plants 5 through 8. Samsung Biologics will continue to accelerate excellence for a healthier future and bolster its standing as a leading CDMO by expanding its capacity, portfolio and global presence.

 


SamsungBiologics_Plant4_Article_3.jpg
SamsungBiologics_Plant4_Article_4.jpg
SamsungBiologics_Plant4_Article_5.jpg
Opening ceremony of Plant 4 (Oct. 2022)

 

 

 

Related Content


YouTube The Future of Biopharma: Plant 4

YouTube Samsung Biologics Plant 4: Specs & Features

 

Samsung_Biologics?_Super_Plant%204_How_the_world?s_largest_biomanufacturing_plant_will_drive_clients?_success_thumbnail.jpg
 

This month, Samsung Biologics commenced GMP operations at its newest Plant 4. With the world’s largest contract manufacturing capacity, the company plans to maximize operational efficiency for its clients and further strengthen its foothold in the industry as an end-to-end service partner.

 

 

Breaking world records

 

In just 23 months since its groundbreaking in November 2020, Samsung Biologics delivered on its commitment to begin partial operations at Plant 4.

 

As the world’s largest single biomanufacturing plant, Plant 4 is expected to have a production capacity of 240,000 liters upon full completion next year, giving Samsung Biologics a total of 604,000 liters’ capacity, amounting to over a quarter of the total global CDMO production, at Bio Campus I.

 

SamsungBiologics_Plant4_Article_1.jpg

Plant 4 groundbreaking ceremony (Nov. 2020)

 

SamsungBiologics_Plant4_Article_2.jpg

Samsung Biologics’ total manufacturing capacity

 

Samsung Biologics offers end-to-end services, from early stage development to commercial manufacturing, including quality management. The company also has a diverse lineup of bioreactors, from 1,000 liters to 15,000 liters, enabling flexibility for small batch clinical trial materials production or large-scale commercial manufacturing.

 

Samsung Biologics can swiftly and efficiently manufacture high-quality biopharmaceuticals based on N-1 perfusion technology, data digitalization and cyber security integrity. Plant 4 incorporates the know-how, technologies and best practices learned at Plants 1, 2 and 3.

 

 


Investing in a sustainable tomorrow

 

As a sustainable CDMO, Samsung Biologics invested in eco-friendly technology throughout Plant 4 to mitigate its emissions. A 1,300 kW solar power generator was installed on the plant’s roof over an area of 4,000 to partially generate energy for the plant.

 

In order to reduce direct GHG emissions, the company adopted the ‘Factory Energy Management System,’ to monitor and analyze energy consumption to help reduce emissions and waste. Through its environmental management strategy, the company plans to take additional measures going forward to enhance its recycling process when it comes to disposables and water use, reduce energy consumption by switching to high-efficiency boilers, and prevent air pollution to help tackle climate change.

 

SamsungBiologics_Plant4_Article_2-1.jpg
Solar panels installed on Plant 4

 

 

 

Accelerating excellence

 

Plant 4 can handle a product’s entire production life cycle within a single site. It will also be equipped with multiple digital solutions to achieve data integrity and transparency, while eliminating the potential of human error.

 

Samsung Biologics plans to further boost client satisfaction through continuous innovation and investments, as well as the construction of Bio Campus II, which will host Plants 5 through 8. Samsung Biologics will continue to accelerate excellence for a healthier future and bolster its standing as a leading CDMO by expanding its capacity, portfolio and global presence.

 

 

SamsungBiologics_Plant4_Article_3.jpg
SamsungBiologics_Plant4_Article_4.jpg
SamsungBiologics_Plant4_Article_5.jpg
Opening ceremony of Plant 4 (Oct. 2022)

 

 

 

Related Content


YouTube The Future of Biopharma: Plant 4

YouTube Samsung Biologics Plant 4: Specs & Features

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Subscribe to our newsletter to download.
*If you have already subscribed, enter your email.

뉴스레터 구독 서비스 유무 확인
Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION

Copyright Samsung Biologics. All rights reserved